Fig. 2: Concordance and divergence in the WHO-5 and ICC classification of TP53-mutated (TP53mut) myeloid neoplasm (MN). | Blood Cancer Journal

Fig. 2: Concordance and divergence in the WHO-5 and ICC classification of TP53-mutated (TP53mut) myeloid neoplasm (MN).

From: Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

Fig. 2

A Sankey plot depicting the divergences between the two classifications of TP53mut MN. B heterogeneity in the overall survival (OS) of WHO-5 classified monoallelic TP53 when reclassified using ICC criteria. C According to WHO-5, 90.9% of TP53mut acute myeloid leukemia (AML) were classified as AML-myelodysplasia related (MR), followed by acute erythroid leukemia (AEL, 7%). D OS of AML with TP53mut with variant allele frequency (VAF) ≥ 10% was significantly poorer compared to AML TP53mut with VAF < 10%; and E OS of TP53mut AML was significantly worse than TP53 wild type (TP53wt) AML-MR.

Back to article page